Company newsCompany release
Intellia Therapeutics presents additional lonvo-z data at ACAAI 2026
Intellia Therapeutics also plans an investor webcast on November 12, 2026, at 10:00 a.m. ET on the data and its launch preparations.
GetSignal
Intellia Therapeutics said on November 12, 2026, that it had highlighted data from seven presentations on lonvoguran ziclumeran (lonvo-z) at the American College of Allergy, Asthma & Immunology (ACAAI) 2026 Annual Scientific Meeting in Phoenix, Arizona.
The company said it will host an investor webcast on the same day at 10:00 a.m. ET to review certain of the data, hear from key opinion leaders and discuss preparations for a planned commercial launch of lonvo-z in hereditary angioedema (HAE).
Key facts
- Location
- Phoenix, Arizona
- Presentations
- Seven at ACAAI 2026 Annual Scientific Meeting
- Investor webcast
- November 12, 2026, 10:00 a.m. ET
Source: The company's release on GlobeNewswire, November 12, 2026.
Written by GetSignal with AI from the company's press release. How we make news
Not investment advice.
More company news
Intellia Therapeutics first, then the newest- Intellia Therapeutics grants inducement awards to three new employees
NTLA · Intellia Therapeutics · Company release · Nov 6, 2026
- Western Digital stockholders elect nine directors at annual meeting
WDC · Western Digital · Form 8-K · Nov 20, 2026
- Ares Capital subsidiary amends BNP Paribas funding facility
ARCC · Ares Capital · Form 8-K · Nov 20, 2026
- FACT II Acquisition extends business combination deadline to November 25, 2027
FACT · FACT II Acquisition · Form 8-K · Nov 20, 2026
